Novartis (NOTA) – tečaj delnic in novice

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia

Vizitka: Novartis

Generalni direktorVasant Narasimhan

Št. zaposlenih75,3 tis.

Ustanovljeno7. mar. 1996

SedežBasel, Basel, Švica

Sektor-

Spletno mestonovartis.com

Vse vrednosti v valuti USD	sep. 2025	dec. 2025	mar. 2026	jun. 2026
Prihodek	14,36 mrd.	13,86 mrd.	13,52 mrd.	14,95 mrd.
Strošek prodanega blaga	3,54 mrd.	3,54 mrd.	3,44 mrd.	3,68 mrd.
Stroški materiala in storitev	3,54 mrd.	3,54 mrd.	3,44 mrd.	3,68 mrd.
Stroški raziskav in razvoja	2,86 mrd.	2,84 mrd.	2,78 mrd.	2,74 mrd.
Skupni stroški raziskav in razvoja	-	-	-	-
Stroški prodaje, splošni in administrativni stroški	3,30 mrd.	3,44 mrd.	3,14 mrd.	3,23 mrd.
Operativni strošek	6,24 mrd.	6,46 mrd.	5,96 mrd.	6,10 mrd.
Skupni operativni stroški	9,77 mrd.	10,00 mrd.	9,40 mrd.	9,78 mrd.
Prihodek iz poslovanja	4,58 mrd.	3,86 mrd.	4,12 mrd.	5,18 mrd.
Drug prihodek, ki ne izhaja iz poslovanja	−7,00 mio.	−130,00 mio.	4,00 mio.	19,00 mio.
Zaslužek pred obdavčitvijo z vključenimi izrednimi postavkami	4,20 mrd.	3,22 mrd.	3,84 mrd.	4,27 mrd.
Zaslužek pred obdavčitvijo brez izrednih postavk	4,29 mrd.	3,49 mrd.	3,78 mrd.	4,73 mrd.
Odhodek iz obdavčitve dobička	266,00 mio.	814,00 mio.	683,00 mio.	1,01 mrd.
Dejanska davčna stopnja	6,34 %	25,30 %	17,79 %	23,71 %
Drugi operativni stroški	70,00 mio.	190,00 mio.	42,00 mio.	127,00 mio.
Čisti prihodek	3,93 mrd.	2,41 mrd.	3,16 mrd.	3,26 mrd.
Neto stopnja dobička	27,36 %	17,38 %	23,34 %	21,83 %
Čisti dobiček na delnico	2,25	2,03	1,99	2,41
Prihodki iz obresti in naložb	-	373,00 mio.	-	-
Obrestni odhodki	−281,00 mio.	−304,00 mio.	−343,00 mio.	−462,00 mio.
Neto obrestni odhodki	−281,00 mio.	69,00 mio.	−343,00 mio.	−462,00 mio.
Stroški amortizacije	-	-	-	-
EBITDA	5,78 mrd.	4,96 mrd.	5,24 mrd.	6,30 mrd.
Dobiček ali izguba pri prodaji sredstev	81,00 mio.	80,00 mio.	−159,00 mio.	−247,00 mio.

Vprašajte kar koli